专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US5849575A Cloning and expression of host-protective immunogens of IBDV 失效
标题翻译： IBDV的宿主保护性免疫原的克隆和表达
公开(公告)号：US5849575A
公开(公告)日：1998-12-15
申请号：US481140
申请日：1995-06-07
申请人： Ahmed Abdullah Azad , Peter John Hudson , Kevin John Fahey
发明人： Ahmed Abdullah Azad , Peter John Hudson , Kevin John Fahey
IPC分类号： C12N15/09 , A61K39/00 , A61K39/215 , A61P31/12 , C07K14/08 , C07K14/165 , C07K16/10 , C12N1/20 , C12N1/21 , C12P21/02 , C12R1/19 , A61K39/12 , C07H21/04
CPC分类号： C07K14/005 , C07K16/10 , A61K39/00 , C12N2720/10022
摘要： A recombinant DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of IBDV RNA, particularly the IBDV RNA segment of approximately 3400 b.p. In particular, a DNA molecule coding for all or a part of at least one structural protein of IBDV, for example, the 32 Kd and/or the 41/37 Kd structural proteins. Synthetic peptides or polypeptides, and fused polypeptides, prepared by expression of host cells containing these DNA molecules are also disclosed.
摘要翻译：重组DNA分子，其包含基本上对应于IBDV RNA的全部或部分的核苷酸序列，特别是约3400bp的IBDV RNA片段。特别地，编码IBDV的全部或部分至少一种结构蛋白的DNA分子，例如32Kd和/或41 / 37Kd结构蛋白。还公开了通过表达含有这些DNA分子的宿主细胞制备的合成肽或多肽和融合多肽。

42. 发明授权

US5811104A Recombinant structural and non-structural proteins of FIPV and method of immunizing 失效
标题翻译： FIPV的重组结构和非结构蛋白和免疫方法
公开(公告)号：US5811104A
公开(公告)日：1998-09-22
申请号：US437362
申请日：1995-05-09
申请人： Beverly Dale , Miles Yamanaka , William M. Acree , Lloyd G. Chavez, Jr.
发明人： Beverly Dale , Miles Yamanaka , William M. Acree , Lloyd G. Chavez, Jr.
IPC分类号： G01N33/569 , A61K39/00 , A61K39/215 , C07K14/00 , C07K14/165 , C07K14/705 , C07K16/00 , C07K16/10 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/50 , C12N15/863 , C12P21/02 , C12P21/08 , C12R1/91 , A61K39/12 , C12N15/00
CPC分类号： C12N15/86 , C07K14/005 , C07K16/10 , A61K39/00 , C12N2710/24143 , C12N2770/20022
摘要： The present invention relates to the development of an efficacious vaccine against Feline Infectious Peritonitis Virus (FIPV). The invention provides the tools for the synthesis and manipulation of the structural and non-structural proteins of FIPV. These proteins are able to elicit an immune response in cats against FIPV. The recombinant virus vectors which express the E1 or N proteins of the virus or the recombinant produced viral proteins themselves are able to elicit an immune response.
摘要翻译：本发明涉及针对猫传染性腹膜炎病毒（FIPV）的有效疫苗的开发。本发明提供了用于FIPV的结构和非结构蛋白质的合成和操作的工具。这些蛋白质能够引发猫对FIPV的免疫反应。表达病毒的E1或N蛋白或重组产生的病毒蛋白本身的重组病毒载体能够引发免疫应答。

43. 发明授权

US5770211A Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease 失效
标题翻译：重组浣熊痘病毒及其作为针对猫传染性腹膜炎病毒病的有效疫苗的用途
公开(公告)号：US5770211A
公开(公告)日：1998-06-23
申请号：US480210
申请日：1995-06-07
申请人： Terri Wasmoen , Lloyd Chavez , Hsien-Jue Chu
发明人： Terri Wasmoen , Lloyd Chavez , Hsien-Jue Chu
IPC分类号： C12N15/09 , A61K39/00 , A61K39/118 , A61K39/12 , A61K39/21 , A61K39/215 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/295 , A61K39/39 , A61P31/12 , C07K14/065 , C07K14/165 , C12N7/00 , C12N7/01 , C12N15/35 , C12N15/863
CPC分类号： C12N15/86 , C07K14/005 , A61K39/00 , C07K2319/00 , C12N2710/24022 , C12N2710/24143 , C12N2770/20022 , Y10S424/819
摘要： This invention provides a recombinant raccoon poxvirus that expresses the nucleocapsid and transmembrane proteins of Feline Infectious Peritonitis Virus. The recombinant viruses are useful as vaccines, either alone or in combination with carriers and adjuvants.
摘要翻译：本发明提供了表达猫传染性腹膜炎病毒的核衣壳和跨膜蛋白的重组浣熊痘病毒。重组病毒可单独或与载体和佐剂组合用作疫苗。

44. 发明授权

US5460815A Feline infectious peritonitis vaccine and method of preparation 失效
标题翻译：猫传染性腹膜炎疫苗及其制备方法
公开(公告)号：US5460815A
公开(公告)日：1995-10-24
申请号：US206268
申请日：1994-03-07
申请人： Richard G. Olsen
发明人： Richard G. Olsen
IPC分类号： C12P21/00 , A61K39/00 , A61K39/215 , A61P31/12 , C07K14/165 , C12N5/10 , C12N7/04 , C12R1/91 , C12N5/06 , C12N7/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/215 , A61K2039/5252 , A61K2039/542 , A61K2039/552 , A61K2039/55566 , A61K39/00 , C12N2770/20022 , C12N2770/20034
摘要： One aspect of the present invention comprises a vaccine for the prevention of disease caused by feline infectious peritonitis virus (FIPV). Such vaccine comprises FIP viral precursor immunogens derived from in vitro produced cells persistently infected with FIPV. Preferred in the production of viral immunogens forming the vaccine of the present invention is the Crandall Feline Kidney (CrFK) cell line. Thus, a second aspect of the invention comprises FIP-infected Crandall Feline Kidney cell line, deposited at the American Type Culture Collection (ATCC), Rockville, MD, on Sep. 23, 1992, and granted Accession No. CRL11137. A third aspect of the invention relates to a method of producing FIP viral precursor immunogens, which comprises culturing in vitro FIP-persistent infected cells in a serum-containing growth medium, subsequently transferring and maintaining said cultured cells in a serum-free medium under conditions and for a time adequate to accumulate FIP viral precursor immunogens shed from said cells, and then separating the cells from the supernatant containing the vital precursor immunogens. The supernatant containing the FIP viral precursor immunogens is blended with a pharmaceutically-acceptable adjuvant in order to form the FIP vaccine disclosed herein.
摘要翻译：本发明的一个方面包括用于预防猫感染性腹膜炎病毒（FIPV）引起的疾病的疫苗。这种疫苗包含衍生自体外产生的细胞的FIP病毒前体免疫原，其持续感染FIPV。形成本发明的疫苗的病毒免疫原的生产中优选的是Crandall Feline Kidney（CrFK）细胞系。因此，本发明的第二方面包括于1992年9月23日保藏于美国典型培养物保藏中心（ATCC），Rockville，MD的FIP感染的Crandall Feline肾细胞系，并授予加入号CRL11137。本发明的第三方面涉及一种生产FIP病毒前体免疫原的方法，其包括在含血清的生长培养基中体外培养FIP-持续感染的细胞，随后在条件下将所述培养的细胞转移并保持在无血清培养基中并且足够的时间积累从所述细胞脱落的FIP病毒前体免疫原，然后从含有重要前体免疫原的上清液中分离细胞。将含有FIP病毒前体免疫原的上清液与药学上可接受的佐剂混合以形成本文公开的FIP疫苗。

45. 发明授权

US5202430A Transmissible gastroenteritis virus genes 失效
标题翻译：传染性胃肠炎病毒基因
公开(公告)号：US5202430A
公开(公告)日：1993-04-13
申请号：US639404
申请日：1991-01-10
申请人： David A. Brian , Paul A. Kapke
发明人： David A. Brian , Paul A. Kapke
IPC分类号： A61K39/00 , C07K14/165
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/20022 , Y10S436/811
摘要： The present invention provides recombinant DNA molecules comprising a sequence encoding a transmissible gastroenteritis virus polypeptide selected from the group consisting of M, N and P, host cells transformed by said recombinant DNA molecule sequences, the M, N and P polypeptides. The present invention also provides subunit vaccines for TGEV.
摘要翻译：本发明提供重组DNA分子，其包含编码由M，N和P组成的组的传染性胃肠炎病毒多肽的序列，由所述重组DNA分子序列转化的宿主细胞，M，N和P多肽。本发明还提供了用于TGEV的亚单位疫苗。

46. 发明授权

US5093258A Recombinant fowlpox virus and recombination vector 失效
标题翻译：重组FOWLPOX病毒和重组载体
公开(公告)号：US5093258A
公开(公告)日：1992-03-03
申请号：US237285
申请日：1988-08-26
申请人： Lawrence K. Cohen , Dennis L. Panicali
发明人： Lawrence K. Cohen , Dennis L. Panicali
IPC分类号： A61K39/00 , A61K39/012 , C07K14/165 , C07K14/455 , C12N7/01 , C12N15/863
CPC分类号： C12N15/86 , A61K39/012 , C07K14/005 , C07K14/455 , A61K39/00 , C12N2710/24043 , C12N2770/20022
摘要： Recombinant fowlpox virus (FPV) capable of expressing immunogenic proteins of fowl pathogens are described. The FPV express DNA of the pathogen under the direction of FPV promoters. The recombinant FPV provide live vaccines for poultry and other animals.
摘要翻译：描述能够表达家禽病原体的免疫原性蛋白质的重组禽痘病毒（FPV）。 FPV在FPV启动子的指导下表达病原体的DNA。重组FPV为家禽和其他动物提供活疫苗。

47. 发明公开

US20240287144A1 SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES 审中-公开
公开(公告)号：US20240287144A1
公开(公告)日：2024-08-29
申请号：US18615011
申请日：2024-03-25
申请人： The USA, as represented by the Secretary, Department of Health and Human Services
发明人： Peter Kwong , Ivelin Georgiev , Michael Gordon Joyce , Masaru Kanekiyo , Aliaksandr Druz , Ulrich Baxa , Joseph Van Galen , Cheng Cheng , John Mascola , Yaroslav Tsybovsky , Yongping Yang , Barney Graham , Syed Mohammad Moin , Jeffrey Boyington
IPC分类号： C07K14/11 , A61K39/00 , A61K39/21 , C07K14/08 , C07K14/16 , C07K14/165 , C07K14/435 , C12N7/00
CPC分类号： C07K14/11 , A61K39/21 , C07K14/082 , C07K14/162 , C07K14/165 , C07K14/43563 , C12N7/00 , A61K2039/55555 , C07K2319/735 , C12N2740/16134 , C12N2760/16134 , C12N2770/20034
摘要： Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

48. 发明授权

US11939356B2 Self-assembling insect ferritin nanoparticles 有权
公开(公告)号：US11939356B2
公开(公告)日：2024-03-26
申请号：US17202231
申请日：2021-03-15
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services
发明人： Peter Kwong , Ivelin Georgiev , Michael Gordon Joyce , Masaru Kanekiyo , Aliaksandr Druz , Ulrich Baxa , Joseph Van Galen , Cheng Cheng , John Mascola , Yaroslav Tsybovsky , Yongping Yang , Barney Graham , Syed Mohammad Moin , Jeffrey Boyington
IPC分类号： C07K14/11 , A61K39/21 , C07K14/08 , C07K14/16 , C07K14/165 , C07K14/435 , C12N7/00 , A61K39/00
CPC分类号： C07K14/11 , A61K39/21 , C07K14/082 , C07K14/162 , C07K14/165 , C07K14/43563 , C12N7/00 , A61K2039/55555 , C07K2319/735 , C12N2740/16134 , C12N2760/16134 , C12N2770/20034
摘要： Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

49. 发明授权

US11896677B2 Compositions and methods for delivery of RNA 有权
公开(公告)号：US11896677B2
公开(公告)日：2024-02-13
申请号：US18357280
申请日：2023-07-24
申请人： HDT Bio Corp.
发明人： Amit Khandhar , Steven Reed , Malcolm Duthie , Jesse Erasmus , Darrick Carter , Bryan J. Berube
IPC分类号： A61K47/69 , A61K9/107 , A61K31/7105 , A61K31/711 , A61K47/02 , A61K47/44 , A61P31/14 , A61K9/127 , A61K39/215 , C12N15/86 , A61K9/51 , A61K31/713 , A61K39/39 , A61K49/18 , C07K14/165 , C12N15/88 , B82Y5/00 , B82Y25/00 , B82Y30/00 , B82Y40/00 , A61K39/00 , A61K47/54 , A61K47/10 , A61K47/26
CPC分类号： A61K47/6907 , A61K9/1075 , A61K9/127 , A61K9/5115 , A61K9/5123 , A61K31/711 , A61K31/713 , A61K31/7105 , A61K39/215 , A61K39/39 , A61K47/02 , A61K47/44 , A61K47/6911 , A61K47/6923 , A61K49/183 , A61K49/1833 , A61P31/14 , C07K14/165 , C12N15/86 , C12N15/88 , A61K47/10 , A61K47/26 , A61K47/547 , A61K2039/55555 , B82Y5/00 , B82Y25/00 , B82Y30/00 , B82Y40/00 , C12N2770/36143
摘要： The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

50. 发明公开

US20240016921A1 ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE 审中-公开
公开(公告)号：US20240016921A1
公开(公告)日：2024-01-18
申请号：US18355601
申请日：2023-07-20
申请人： Akston Biosciences Corporation
发明人： Todd C. Zion , Thomas M. Lancaster , Thillainayagam Sathiyaseelan , Kexin Huang
IPC分类号： A61K39/215 , A61P31/14 , C07K14/165 , C12N7/00
CPC分类号： A61K39/215 , A61P31/14 , C07K14/165 , C12N7/00 , A61K38/00
摘要： The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式